These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 11405532

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. IL-5 and IL-5 receptor in asthma.
    Kotsimbos AT, Hamid Q.
    Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():75-91. PubMed ID: 9698919
    [Abstract] [Full Text] [Related]

  • 4. Cytokine antagonists for the treatment of asthma: progress to date.
    Antoniu SA.
    BioDrugs; 2009; 23(4):241-51. PubMed ID: 19697966
    [Abstract] [Full Text] [Related]

  • 5. The allergen-induced airway hyperresponsiveness in a human-mouse chimera model of asthma is T cell and IL-4 and IL-5 dependent.
    Tournoy KG, Kips JC, Pauwels RA.
    J Immunol; 2001 Jun 01; 166(11):6982-91. PubMed ID: 11359860
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-5 and eosinophils induce airway damage and bronchial hyperreactivity during allergic airway inflammation in BALB/c mice.
    Hogan SP, Koskinen A, Foster PS.
    Immunol Cell Biol; 1997 Jun 01; 75(3):284-8. PubMed ID: 9243294
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-4 and interleukin-5 as targets for the inhibition of eosinophilic inflammation and allergic airways hyperreactivity.
    Foster PS, Hogan SP, Matthaei KI, Young IG.
    Mem Inst Oswaldo Cruz; 1997 Jun 01; 92 Suppl 2():55-61. PubMed ID: 9698916
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ursolic acid, a potential PPARγ agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma.
    Kim SH, Hong JH, Lee YC.
    Eur J Pharmacol; 2013 Feb 15; 701(1-3):131-43. PubMed ID: 23201068
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reassessing the Th2 cytokine basis of asthma.
    O'Byrne PM, Inman MD, Adelroth E.
    Trends Pharmacol Sci; 2004 May 15; 25(5):244-8. PubMed ID: 15120489
    [Abstract] [Full Text] [Related]

  • 12. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
    Stein ML, Munitz A.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov 15; 4(3):201-9. PubMed ID: 20807192
    [Abstract] [Full Text] [Related]

  • 13. Cytokine modulators as novel therapies for asthma.
    Barnes PJ.
    Annu Rev Pharmacol Toxicol; 2002 Nov 15; 42():81-98. PubMed ID: 11807165
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY, Sur S, Grant JA, Tripple JW.
    Curr Opin Allergy Clin Immunol; 2019 Feb 15; 19(1):30-37. PubMed ID: 30407206
    [Abstract] [Full Text] [Related]

  • 15. Advances in immunopharmacology of asthma.
    Wong WS, Koh DS.
    Biochem Pharmacol; 2000 Jun 01; 59(11):1323-35. PubMed ID: 10751541
    [Abstract] [Full Text] [Related]

  • 16. Cytokines as targets for the inhibition of eosinophilic inflammation.
    Hogan SP, Foster PS.
    Pharmacol Ther; 1997 Jun 01; 74(3):259-83. PubMed ID: 9352584
    [Abstract] [Full Text] [Related]

  • 17. The use of biologic therapies for the management of pediatric asthma.
    Lovinsky-Desir S.
    Pediatr Pulmonol; 2020 Mar 01; 55(3):803-808. PubMed ID: 31880870
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pistacia integerrima ameliorates airway inflammation by attenuation of TNF-α, IL-4, and IL-5 expression levels, and pulmonary edema by elevation of AQP1 and AQP5 expression levels in mouse model of ovalbumin-induced allergic asthma.
    Rana S, Shahzad M, Shabbir A.
    Phytomedicine; 2016 Jul 15; 23(8):838-45. PubMed ID: 27288919
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B, Xue L, Pavord ID.
    Ther Adv Respir Dis; 2015 Aug 15; 9(4):135-45. PubMed ID: 25900924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.